Henry Schein Raises FY2026 Guidance on Strong Q2 Performance
Event summary
- Henry Schein reported $3.5 billion in total net sales for Q2 2026, up 6.7% YoY.
- Non-GAAP net income rose to $145 million, or $1.27 per diluted share, from $135 million a year earlier.
- The company raised its FY2026 guidance for non-GAAP diluted EPS to $5.29-$5.39 and total sales growth to 4.5%-5.5%.
- Henry Schein repurchased approximately 2.6 million shares during Q2 2026, totaling $200 million.
The big picture
Henry Schein's strong Q2 performance reflects sustained momentum across its healthcare solutions businesses. The company is focusing on value creation initiatives, operational rigor, and deepening customer relationships to drive sustainable shareholder value. This strategic focus aligns with broader industry trends toward consolidation and efficiency in the healthcare distribution sector.
What we're watching
- Execution Risk
- Whether Henry Schein can sustain its value creation initiatives and operational rigor to meet raised guidance.
- Market Dynamics
- How global economic conditions, including foreign currency exchange rates, will impact sales growth.
- Strategic Focus
- The pace at which Henry Schein can accelerate growth and simplify its business while deepening customer relationships.
Related topics